锦欣生殖医疗集团有限公司（01951）于2026年9月1日发布公告，披露当天在香港联交所场内回购股份事项。
本次回购股份数量为1,343,000股，占回购前公司已发行股本（不包括库藏股）约0.0498%。回购价在每股2.20港元至2.25港元之间，总耗资约2,998,912.50港元（约299.89万港元）。回购完成后，公司已发行股本（不包括库藏股）数量为2,697,034,043股，库藏股数量为8,010,000股，总股本保持2,705,044,043股不变。
根据公告，股东大会已于2026年6月25日通过购回授权，授权额度为262,511,954股。公司已在香港联交所或其他证券交易所累计回购股份20,551,500股，占授权决议通过当日已发行股本约0.7829%。公司确认已遵守香港联交所证券上市规则及相关法例规定。公告由董事董阳签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.